KEGG   DRUG: Reslizumab
Entry
D08985                      Drug                                   
Name
Reslizumab (USAN);
Cinqaero (TN);
Cinqair (TN)
Product
Class
Immunological agent
 DG02019  Interleukin inhibitor
Remark
ATC code: R03DX08
Product: D08985<US>
Efficacy
Antiasthmatic, Anti-IL-5 antibody
  Disease
Asthma, eosinophilic phenotype [DS:H00079]
  Type
Monoclonal antibody
Target
IL5 [HSA:3567] [KO:K05428]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04630  JAK-STAT signaling pathway
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 R RESPIRATORY SYSTEM
  R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
   R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
    R03DX Other systemic drugs for obstructive airway diseases
     R03DX08 Reslizumab
      D08985  Reslizumab (USAN) <US>
USP drug classification [BR:br08302]
 Respiratory Tract/Pulmonary Agents
  Respiratory Tract Agents, Other
   Immunomodulators
    Reslizumab
     D08985  Reslizumab (USAN)
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D08985  Reslizumab
Drug classes [BR:br08332]
 Immunological agent
  DG02019  Interleukin inhibitor
   D08985  Reslizumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Interleukins
    IL5
     D08985  Reslizumab (USAN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D08985
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D08985
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D08985
Other DBs
CAS: 241473-69-8
PubChem: 96025668
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system